Photo: <a href="https://depositphotos.com" target="_blank">Depositphotos</a>
Sep 22, 2025, 12:43
AQUATIC Trial: Validates Stopping ASA Improves Safety and Efficacy in CAD
Christopher Cannon, Editor in Chief, Harvard Health Publishing, shared a post on LinkedIn:
“Very important trial: AQUATIC: dropping ASA in CAD patients on anticoagulation improves both safety – and efficacy!
This validates the prior findings from the AFIRE trial.
For patients on anticoagulation, we need to look to stop the aspirin for long-term treatment.”
Read full article here.
Title: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation
Authors: Gilles Lemesle, Romain Didier, Philippe Gabriel Steg, Tabassome Simon, Gilles Montalescot, Nicolas Danchin, Christophe Bauters
Stay updated with Hemostasis Today.
AFIRE Trial
Anticoagulation
AQUATIC
ASA
Aspirin
CAD
Christophe Bauters
Christopher Cannon
Chronic Coronary Syndrome
Gilles Lemesle
Gilles Montalescot
Headlines
Health
Hematology
Hemostasis
Hemostasis Today
Medicine
Nicolas Danchin
Oral Anticoagulation
Philippe Gabriel Steg
Romain Didier
Tabassome Simon
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall
-
Jun 10, 2026, 17:51Mariam Swidan: Some Red Blood Cells Can’t Handle Pressure
-
Jun 10, 2026, 17:49Ankit Mathur: Hosting ISBT Academy Day on Rare Donor Program in India
-
Jun 10, 2026, 17:48Shadi Tabibian: When Patients Bleed but Standard Testing Is Normal